3 Reasons Celgene’s Investors Should Applaud the Juno Therapeutics Buyout – Motley Fool
|
3 Reasons Celgene's Investors Should Applaud the Juno Therapeutics Buyout
Motley Fool Specifically, the company is working on an exciting new type of treatment called chimeric antigen receptor T–cell therapy, or CAR-T. This therapy extracts a patient's T–cells and then reprograms them to be able to identify cancer. Once complete, they … |
